FROZENFLAME
3 years ago
Allakos Inc. (the โCompanyโ or โAllakosโ) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported data from ENIGMA 2, a 24-week Phase 3 randomized, double-blind, placebo-controlled study of lirentelimab in patients with biopsy confirmed eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and KRYPTOS, a 24-week Phase 2/3 randomized, double-blind, placebo-controlled study of lirentelimab in patients with biopsy-confirmed eosinophilic esophagitis (EoE). Both ENIGMA 2 and KRYPTOS studies met their histologic co-primary endpoints, but did not achieve statistical significance on the patient reported symptomatic co-primary endpoints.
โWe are deeply disappointed that the studies did not achieve their symptomatic endpoints,โ said Robert Alexander, PhD, Chief Executive Officer of Allakos. โThe company is grateful to the patients with eosinophilic gastrointestinal diseases (EGIDs) and to the investigators who participated in the ENIGMA and KRYPTOS trials.โ
Inves2day
3 years ago
Allakos holders - please read and share the link below.
Stock wash sale 30 days period ended on 21 January 2022. December sellers will be looking to buy back now. Two after hours buys yesterday make more sense now.
ALLK is a forgotten share, but not for those who have to buy it back. The seller is gone for two days, but the sentiment is negative around all Nasdaq shares hence negative ends on Thu and Fr. This will change too.
I saw on Thursday 20 January that there was an appetite to climb up, really. Virtually no seller around. During the day all was going well, MMs were ticking it nicely higher until that moment of crash caused by Netflix followed by the entire Nasdaq falling down. Friday Nasdaq still down so ALLK too. But every crash ends and reversal starts for new buyers.
Look, as ALLK holders, we all can and have to create a need for shorters and those who sold in December for tax reasons to start the buy back. We need an bigger action to close day at 5-10% up to get noticed in media.
I. e. ADGI reversed exactly after 30 days wash sale. Allakos can do the same if we really want it.
Sell only if you really have to or Hold it for a few more days to see if recovery kicks in with Nasdaq stabilising.
Allakos Inc at $7 mcap is slightly lower than cash and equivalents.
We know they did not deliver but ffs share is down from $84 to $7 and they still be looking to use thst drug in another areas.
Please share the below post on Twitter for awareness.
https://twitter.com/inves2day/status/1485023226753437698?t=aK2TQngCviUwopFKMOEmjQ&s=19
Thank you for reading and sharing.
*23 Jan - my account on StockTwits has been suspended after posting the above link*
donwillems
3 years ago
well this has 3 stages for me, everything +9.50, allright
everything above 10+, superb
everything above 12.50, winner winner chicken dinner.
A company with 500 million up their sleeves, I think they might figure something out.
And whats more, why did I buy into this company?
I have EOE myself, it's being triggered by cow milk with me and my throat and stumach gets hurt really bad by the eosiphiniles If I don't watch out with avoiding everything with milk.
I'm totally wondered here how that however the drug significantly reducing the eosiphiniles in situ doesn't get a response on the symptons, this starts me wondering if the direct symptons only thrive by the (food)allergy people have with it.
For now, I avoid milk and use omeprazole to completly suppres the effects, corticosteriod can be used locally but they are bad for blood vessels long term.
To get to the point, I think this drug isn't wrote off at all, the eosiphiniles do damage the throat a lot long term in this disease, if left untreathed, the throat will start forming circular scars, making it smaller and making it long term impossible to get food into the stumach.
The research completly ignores this problem, while it's the second main cause for treating this disease, unimaginable if you ask me.